Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Wilkinson

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
Clinical Pharmacology and Therapeutics|December 1, 1993
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy menM T Kinirons, D O'Shea, T E Downing, et al.
Gastroenterology|December 1, 1981
Normal metabolism of morphine in cirrhosisR V Patwardhan, R F Johnson, A Hoyumpa, et al.
Clinical Pharmacology and Therapeutics|June 1, 1992
The disposition of dapsone in cirrhosisD G May, P A Arns, W O Richards, et al.
Clinical Pharmacology and Therapeutics|June 1, 1978
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in manA Rane, O Oelz, J C Frolich, et al.
Carcinogenesis|September 1, 1994
Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activityM Romkes-Sparks, A Mnuskin, H D Chern, et al.
The Journal of Clinical Investigation|February 1, 1984
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervalsE L Carey, H J Duff, D M Roden, et al.
Clinical Pharmacology and Therapeutics|July 1, 1986
Encainide disposition in patients with renal failureR H Bergstrand, T Wang, D M Roden, et al.
Dalton Transactions (Cambridge, England : 2003)|July 29, 2021
Comparing coordination uranyl(vi) complexes with 2-(1H-imidazo[4,5-b]phenazin-2-yl)phenol and derivativesE A Hiti, G R Wilkinson, I R Ariyarathna, et al.
Molecular Pharmacology|July 17, 2001
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African AmericansL J Dickmann, A E Rettie, M B Kneller, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Clinical Pharmacology and Therapeutics|December 1, 1993
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy menM T Kinirons, D O'Shea, T E Downing, et al.
Gastroenterology|December 1, 1981
Normal metabolism of morphine in cirrhosisR V Patwardhan, R F Johnson, A Hoyumpa, et al.
Clinical Pharmacology and Therapeutics|June 1, 1992
The disposition of dapsone in cirrhosisD G May, P A Arns, W O Richards, et al.
Clinical Pharmacology and Therapeutics|June 1, 1978
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in manA Rane, O Oelz, J C Frolich, et al.
Carcinogenesis|September 1, 1994
Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activityM Romkes-Sparks, A Mnuskin, H D Chern, et al.
The Journal of Clinical Investigation|February 1, 1984
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervalsE L Carey, H J Duff, D M Roden, et al.
Clinical Pharmacology and Therapeutics|July 1, 1986
Encainide disposition in patients with renal failureR H Bergstrand, T Wang, D M Roden, et al.
Dalton Transactions (Cambridge, England : 2003)|July 29, 2021
Comparing coordination uranyl(vi) complexes with 2-(1H-imidazo[4,5-b]phenazin-2-yl)phenol and derivativesE A Hiti, G R Wilkinson, I R Ariyarathna, et al.
Molecular Pharmacology|July 17, 2001
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African AmericansL J Dickmann, A E Rettie, M B Kneller, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
Pageof 19